Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 7,301 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 7,301 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $207,932.48. Following the completion of the transaction, the insider directly owned 177,957 shares of the company’s stock, valued at $5,068,215.36. This represents a 3.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Friday, August 21st, Jason Adair sold 73,631 shares of Liquidia stock. The stock was sold at an average price of $69.09, for a total transaction of $5,087,165.79.
• On Monday, July 27th, Jason Adair sold 688 shares of Liquidia stock. The stock was sold at an average price of $87.53, for a total value of $60,220.64.

Liquidia Stock Down 3.1%

Liquidia stock opened at $26.81 on Wednesday. The firm has a market capitalization of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a twelve month low of $21.94 and a twelve month high of $93.61. The stock’s fifty day simple moving average is $63.40 and its 200-day simple moving average is $61.76.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The company had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company’s revenue for the quarter was up 1842.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.49) earnings per share. As a group, equities analysts expect that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LQDA shares. Wedbush set a $58.00 price target on Liquidia in a research report on Friday, October 2nd. BTIG Research lowered shares of Liquidia from a “buy” rating to a “neutral” rating in a research note on Thursday, October 1st. HC Wainwright reduced their target price on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, October 2nd. Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Raymond James Financial reiterated an “outperform” rating on shares of Liquidia in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $83.69.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of LQDA. Globeflex Capital L P purchased a new position in Liquidia in the second quarter valued at $175,000. Nykredit A S purchased a new stake in Liquidia during the 2nd quarter worth about $177,000. Hurley Capital LLC lifted its holdings in Liquidia by 140.7% during the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock worth $179,000 after buying an additional 3,040 shares during the last quarter. Apollon Wealth Management LLC purchased a new stake in Liquidia during the 1st quarter worth about $247,000. Finally, Archer Investment Corp acquired a new position in shares of Liquidia during the 1st quarter worth about $259,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).